Outcomes of patients (pts) receiving emetogenic chemotherapy (CT): How do oncologist's (MD's) practice patterns of antiemetic prescribing change after pts experience acute or delayed CINV?

8256 BackgroundIn order to understand MD's practice patterns & pt outcomes of AE therapy we conducted an observational study at 10 US sites. Methods 114 pts receiving emetogenic CT (90% Hesketh 4 or 5) recorded emetic episodes (EE) & nausea scores during 1st (C1) & 2nd (C2) cycles of CT. MD prescriptions & pt diaries were used to determine compliance (Comp) w/ ASCO or MASCC AE guidelines (AEG). CINV = either EE or nausea > 5mm on VAS. ResultsPts were mostly women (80.7 %), mean age 56 yrs. Cancer diagnoses: breast (55%), lung (13%) & lymphoma (12%). For C1 +C2, acute AE were 5HT3 RA + steroids ± other agents (191), 5HT3 RA w/o steroids ± other agents (31) & other (4). Delayed AE included 5HT3 RA + D2 receptor blockers (112), D2 receptor blockers alone (27), none (9), steroid-based AE (40) & single-agent 5HT3 RA (9). Failure rates & compliance w/ G are shown below. A-CINV Comp D-CINV Comp Of the 37 pts w/ A-CINV in C1,6 didn't receive G-based care & only 1 of these received G-based AE in C2. Of the 67 pts ...